PH26978A - Method of using (2-imidazolin-2-ylamino)quinozalines to reduce or maintain intraocular pressure - Google Patents

Method of using (2-imidazolin-2-ylamino)quinozalines to reduce or maintain intraocular pressure Download PDF

Info

Publication number: PH26978A
Authority: PH; Philippines
Prior art keywords: compound; group; mammalian eye; intraocular pressure; imidazolin
Prior art date: 1989-10-31

Application number

PH41224A

Other languages

English (en)

Inventor

Charles Gluchowski

Original Assignee

Allergan Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-10-31

Filing date

1990-09-19

Publication date

1992-12-28

1990-09-19 Application filed by Allergan Inc filed Critical Allergan Inc

1992-12-28 Publication of PH26978A publication Critical patent/PH26978A/en

Links

-1 2-imidazolin-2-ylamino Chemical group 0.000 title claims abstract description 30
230000004410 intraocular pressure Effects 0.000 title claims abstract description 30
238000000034 method Methods 0.000 title claims description 42
150000001875 compounds Chemical class 0.000 claims abstract description 47
239000000203 mixture Substances 0.000 claims abstract description 25
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 22
208000010412 Glaucoma Diseases 0.000 claims abstract description 17
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims abstract description 16
150000003839 salts Chemical class 0.000 claims abstract description 11
239000002253 acid Substances 0.000 claims abstract description 10
229910052794 bromium Inorganic materials 0.000 claims abstract description 8
229910052801 chlorine Inorganic materials 0.000 claims abstract description 6
125000004432 carbon atom Chemical group C* 0.000 claims description 14
WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 6
239000007788 liquid Substances 0.000 claims description 3
125000004429 atom Chemical group 0.000 claims 1
239000001257 hydrogen Substances 0.000 abstract description 10
239000003814 drug Substances 0.000 abstract description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 5
230000000699 topical effect Effects 0.000 abstract description 5
150000002431 hydrogen Chemical group 0.000 abstract description 4
238000004519 manufacturing process Methods 0.000 abstract description 3
125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
239000007787 solid Substances 0.000 description 31
239000000243 solution Substances 0.000 description 28
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 24
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
150000003252 quinoxalines Chemical class 0.000 description 14
238000006243 chemical reaction Methods 0.000 description 13
239000013078 crystal Substances 0.000 description 11
238000002360 preparation method Methods 0.000 description 10
235000002639 sodium chloride Nutrition 0.000 description 10
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
230000000694 effects Effects 0.000 description 9
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
239000012043 crude product Substances 0.000 description 7
239000000463 material Substances 0.000 description 7
XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 7
239000011541 reaction mixture Substances 0.000 description 7
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
238000003756 stirring Methods 0.000 description 6
XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
150000002540 isothiocyanates Chemical class 0.000 description 5
MSGRFBKVMUKEGZ-UHFFFAOYSA-N quinoxalin-6-amine Chemical compound N1=CC=NC2=CC(N)=CC=C21 MSGRFBKVMUKEGZ-UHFFFAOYSA-N 0.000 description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
125000000217 alkyl group Chemical group 0.000 description 4
238000005804 alkylation reaction Methods 0.000 description 4
239000000872 buffer Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
ACYGVAVUNGWGBY-UHFFFAOYSA-N n-(4,5-dihydro-1h-imidazol-2-yl)quinoxalin-2-amine Chemical compound N1CCN=C1NC1=CN=C(C=CC=C2)C2=N1 ACYGVAVUNGWGBY-UHFFFAOYSA-N 0.000 description 4
238000001953 recrystallisation Methods 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
YKFVEQQFGNMNCH-UHFFFAOYSA-N 2-methylquinoxalin-6-amine Chemical compound C1=C(N)C=CC2=NC(C)=CN=C21 YKFVEQQFGNMNCH-UHFFFAOYSA-N 0.000 description 3
IRAOSCSPAYZRJE-UHFFFAOYSA-N 5-bromoquinoxalin-6-amine Chemical compound N1=CC=NC2=C(Br)C(N)=CC=C21 IRAOSCSPAYZRJE-UHFFFAOYSA-N 0.000 description 3
201000002862 Angle-Closure Glaucoma Diseases 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
210000002159 anterior chamber Anatomy 0.000 description 3
210000001742 aqueous humor Anatomy 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
239000002738 chelating agent Substances 0.000 description 3
229940093499 ethyl acetate Drugs 0.000 description 3
235000019439 ethyl acetate Nutrition 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000007789 gas Substances 0.000 description 3
238000007726 management method Methods 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
YOWAEZWWQFSEJD-UHFFFAOYSA-N quinoxalin-2-amine Chemical compound C1=CC=CC2=NC(N)=CN=C21 YOWAEZWWQFSEJD-UHFFFAOYSA-N 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 3
RKMFFOLUBJFMBQ-UHFFFAOYSA-N (4-amino-2-azaniumylphenyl)azanium;dichloride Chemical compound Cl.Cl.NC1=CC=C(N)C(N)=C1 RKMFFOLUBJFMBQ-UHFFFAOYSA-N 0.000 description 2
QBZGAULXCVZXFL-UHFFFAOYSA-N 2,3-dimethylquinoxalin-6-amine Chemical compound C1=C(N)C=C2N=C(C)C(C)=NC2=C1 QBZGAULXCVZXFL-UHFFFAOYSA-N 0.000 description 2
CZWQHNDESNJXGS-UHFFFAOYSA-N 2-methyl-6-nitroquinoxaline Chemical compound C1=C([N+]([O-])=O)C=CC2=NC(C)=CN=C21 CZWQHNDESNJXGS-UHFFFAOYSA-N 0.000 description 2
SQICFWDFYJDZFO-UHFFFAOYSA-N 3-methylquinoxalin-6-amine Chemical compound C1=CC(N)=CC2=NC(C)=CN=C21 SQICFWDFYJDZFO-UHFFFAOYSA-N 0.000 description 2
RAUWPNXIALNKQM-UHFFFAOYSA-N 4-nitro-1,2-phenylenediamine Chemical compound NC1=CC=C([N+]([O-])=O)C=C1N RAUWPNXIALNKQM-UHFFFAOYSA-N 0.000 description 2
CRNMXQMOFAYYEX-UHFFFAOYSA-N 5-bromo-6-isothiocyanatoquinoxaline Chemical compound C1=CN=C2C(Br)=C(N=C=S)C=CC2=N1 CRNMXQMOFAYYEX-UHFFFAOYSA-N 0.000 description 2
PVFOHMXILQEIHX-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-bromophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Br PVFOHMXILQEIHX-UHFFFAOYSA-N 0.000 description 2
208000002177 Cataract Diseases 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
201000001326 acute closed-angle glaucoma Diseases 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
230000029936 alkylation Effects 0.000 description 2
239000000538 analytical sample Substances 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
239000002585 base Substances 0.000 description 2
239000011449 brick Substances 0.000 description 2
125000001246 bromo group Chemical group Br* 0.000 description 2
NVTXFBCAIQXOLE-UHFFFAOYSA-N carbonyl dichloride;hydrate Chemical compound O.ClC(Cl)=O NVTXFBCAIQXOLE-UHFFFAOYSA-N 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000012362 glacial acetic acid Substances 0.000 description 2
229910000037 hydrogen sulfide Inorganic materials 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
238000011587 new zealand white rabbit Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
239000008213 purified water Substances 0.000 description 2
238000011084 recovery Methods 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
238000010183 spectrum analysis Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
VXKWYPOMXBVZSJ-UHFFFAOYSA-N tetramethyltin Chemical compound C[Sn](C)(C)C VXKWYPOMXBVZSJ-UHFFFAOYSA-N 0.000 description 2
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
238000003828 vacuum filtration Methods 0.000 description 2
JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
KIJKTBBMRJFEBK-UHFFFAOYSA-N 1-(2-aminoethyl)-1-(5-bromoquinoxalin-6-yl)thiourea Chemical compound N1=CC=NC2=C(Br)C(N(C(N)=S)CCN)=CC=C21 KIJKTBBMRJFEBK-UHFFFAOYSA-N 0.000 description 1
AJSSTFSYYCHAJW-UHFFFAOYSA-N 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)-2,3-dimethylquinoxalin-6-amine Chemical compound BrC1=C2N=C(C)C(C)=NC2=CC=C1NC1=NCCN1 AJSSTFSYYCHAJW-UHFFFAOYSA-N 0.000 description 1
ICROYPJYNVAMQF-UHFFFAOYSA-N 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)-2-methylquinoxalin-6-amine Chemical compound C1=CC2=NC(C)=CN=C2C(Br)=C1NC1=NCCN1 ICROYPJYNVAMQF-UHFFFAOYSA-N 0.000 description 1
CYQLAWXTEHCJLV-UHFFFAOYSA-N 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)-2-methylquinoxalin-6-amine;2-methyl-6-nitroquinoxaline Chemical compound C1=C([N+]([O-])=O)C=CC2=NC(C)=CN=C21.C1=CC2=NC(C)=CN=C2C(Br)=C1NC1=NCCN1 CYQLAWXTEHCJLV-UHFFFAOYSA-N 0.000 description 1
IAOQEOWQCMGOEP-UHFFFAOYSA-N 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)-3-methylquinoxalin-6-amine Chemical compound BrC=1C2=NC(C)=CN=C2C=CC=1NC1=NCCN1 IAOQEOWQCMGOEP-UHFFFAOYSA-N 0.000 description 1
YKGMGCYABGHZRB-UHFFFAOYSA-N 5-bromoquinoxalin-6-amine;hydrobromide Chemical compound Br.N1=CC=NC2=C(Br)C(N)=CC=C21 YKGMGCYABGHZRB-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
239000004255 Butylated hydroxyanisole Substances 0.000 description 1
239000004322 Butylated hydroxytoluene Substances 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
208000031969 Eye Hemorrhage Diseases 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
206010067684 Iris bombe Diseases 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
206010068960 Narrow anterior chamber angle Diseases 0.000 description 1
208000022873 Ocular disease Diseases 0.000 description 1
206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
206010037520 Pupillary block Diseases 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical class [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
VLWVJEXUZRFVTD-UHFFFAOYSA-N [3-(2-aminoethyl)quinoxalin-2-yl]thiourea Chemical compound C1=CC=C2N=C(NC(N)=S)C(CCN)=NC2=C1 VLWVJEXUZRFVTD-UHFFFAOYSA-N 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
YBZUKWAMZWDJTR-UHFFFAOYSA-N benzene-1,2,4-triamine;hydrochloride Chemical compound Cl.NC1=CC=C(N)C(N)=C1 YBZUKWAMZWDJTR-UHFFFAOYSA-N 0.000 description 1
PUIRIBOEUBQBEV-UHFFFAOYSA-N benzene-1,2,4-triamine;n-(4,5-dihydro-1h-imidazol-2-yl)quinoxalin-6-amine;dihydrochloride Chemical compound Cl.Cl.NC1=CC=C(N)C(N)=C1.N1CCN=C1NC1=CC=C(N=CC=N2)C2=C1 PUIRIBOEUBQBEV-UHFFFAOYSA-N 0.000 description 1
CPEKAXYCDKETEN-UHFFFAOYSA-N benzoyl isothiocyanate Chemical compound S=C=NC(=O)C1=CC=CC=C1 CPEKAXYCDKETEN-UHFFFAOYSA-N 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 1
108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
238000009835 boiling Methods 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
ZWSPHOLDPXOVJP-UHFFFAOYSA-N butane-2,3-dione 2,3-dimethylquinoxalin-6-amine Chemical compound CC(C(C)=O)=O.CC1=NC2=CC=C(C=C2N=C1C)N ZWSPHOLDPXOVJP-UHFFFAOYSA-N 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
229940043253 butylated hydroxyanisole Drugs 0.000 description 1
235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
229940095259 butylated hydroxytoluene Drugs 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
201000005667 central retinal vein occlusion Diseases 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
201000005682 chronic closed-angle glaucoma Diseases 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000013058 crude material Substances 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
230000010339 dilation Effects 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
BXUKAXFDABMVND-UHFFFAOYSA-L disodium;1,2-dihydroxyethane-1,2-disulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C(O)C(O)S([O-])(=O)=O BXUKAXFDABMVND-UHFFFAOYSA-L 0.000 description 1
239000006196 drop Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
229940124274 edetate disodium Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000000416 exudates and transudate Anatomy 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000007774 longterm Effects 0.000 description 1
208000018769 loss of vision Diseases 0.000 description 1
231100000864 loss of vision Toxicity 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
QZUXRMOPAGPTIY-UHFFFAOYSA-N n-(4,5-dihydro-1h-imidazol-2-yl)-5-methylquinoxalin-6-amine Chemical compound C1=CC2=NC=CN=C2C(C)=C1NC1=NCCN1 QZUXRMOPAGPTIY-UHFFFAOYSA-N 0.000 description 1
PVKUNRLEOHFACD-UHFFFAOYSA-N n-(4,5-dihydro-1h-imidazol-2-yl)quinoxalin-6-amine Chemical compound N1CCN=C1NC1=CC=C(N=CC=N2)C2=C1 PVKUNRLEOHFACD-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
229940096826 phenylmercuric acetate Drugs 0.000 description 1
PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000009290 primary effect Effects 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
229960003981 proparacaine Drugs 0.000 description 1
230000001007 puffing effect Effects 0.000 description 1
210000001747 pupil Anatomy 0.000 description 1
239000012264 purified product Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
208000004644 retinal vein occlusion Diseases 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
229940001584 sodium metabisulfite Drugs 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
229940001474 sodium thiosulfate Drugs 0.000 description 1
235000019345 sodium thiosulphate Nutrition 0.000 description 1
239000002904 solvent Substances 0.000 description 1
229910000080 stannane Inorganic materials 0.000 description 1
239000007858 starting material Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
210000001585 trabecular meshwork Anatomy 0.000 description 1
230000008733 trauma Effects 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000004393 visual impairment Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

PH41224A 1989-10-31 1990-09-19 Method of using (2-imidazolin-2-ylamino)quinozalines to reduce or maintain intraocular pressure PH26978A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/429,835 US5021416A (en)	1989-10-31	1989-10-31	Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure

Publications (1)

Publication Number	Publication Date
PH26978A true PH26978A (en)	1992-12-28

Family

ID=23704912

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH41224A PH26978A (en)	1989-10-31	1990-09-19	Method of using (2-imidazolin-2-ylamino)quinozalines to reduce or maintain intraocular pressure

Country Status (18)

Country	Link
US (1)	US5021416A (fr)
EP (1)	EP0426390B1 (fr)
JP (1)	JP2999240B2 (fr)
KR (1)	KR910007530A (fr)
AT (1)	ATE122233T1 (fr)
AU (1)	AU627626B2 (fr)
CA (1)	CA2025189A1 (fr)
DE (1)	DE69019297T2 (fr)
ES (1)	ES2074138T3 (fr)
FI (1)	FI905369A0 (fr)
HU (1)	HU207946B (fr)
IE (1)	IE68413B1 (fr)
IL (1)	IL96083A (fr)
NZ (1)	NZ235884A (fr)
PH (1)	PH26978A (fr)
RU (1)	RU1829937C (fr)
TW (1)	TW218352B (fr)
ZA (1)	ZA908731B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5112822A (en) *	1989-10-12	1992-05-12	Allergan, Inc.	(2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5077292A (en) *	1989-10-12	1991-12-31	Allergan, Inc.	(2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5231096A (en) *	1989-10-12	1993-07-27	Allergan, Inc.	Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5326763A (en) *	1989-10-12	1994-07-05	Allergan, Inc.	Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US6323204B1 (en) *	1993-10-13	2001-11-27	Allergan	Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
WO1995010280A1 (fr) *	1993-10-13	1995-04-20	Allergan	Modes d'utilisation de derives de la quinoxaline (2 - imidazolin - 2 - ylamino)
ATE194771T1 (de) *	1993-12-17	2000-08-15	Procter & Gamble	6-(2-imidazolinylamino) chinoxalin-verbindungen als alpha-2-adrenorezeptoragonisten
US5576437A (en) *	1993-12-17	1996-11-19	The Procter & Gamble Company	7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
BR9408335A (pt) *	1993-12-17	1997-08-19	Procter & Gamble	Composto uso do mesmo e composição farmacêutica
US5578607A (en) *	1993-12-17	1996-11-26	The Procter & Gamble Company	6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
US5478858A (en) *	1993-12-17	1995-12-26	The Procter & Gamble Company	5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US6294563B1 (en)	1994-10-27	2001-09-25	Allergan Sales, Inc.	Combinations of prostaglandins and brimonidine or derivatives thereof
US5856329A (en) *	1995-06-28	1999-01-05	Allergan	Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
US6194415B1 (en) *	1995-06-28	2001-02-27	Allergan Sales, Inc.	Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5916900A (en)	1995-06-29	1999-06-29	The Procter & Gamble Company	7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
NZ504707A (en)	1997-11-24	2002-11-26	Procter & Gamble	5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
US6841684B2 (en)	1997-12-04	2005-01-11	Allergan, Inc.	Imidiazoles having reduced side effects
US6329369B1 (en)	1997-12-04	2001-12-11	Allergan Sales, Inc.	Methods of treating pain and other conditions
US20040214829A1 (en) *	2000-07-14	2004-10-28	Allergan, Inc.	Compositions containing alpha-2-adrenergic agonist components
US8858961B2 (en)	2000-07-14	2014-10-14	Allergan, Inc.	Compositions containing alpha-2-adrenergic agonist components
US20050026924A1 (en) *	2000-07-14	2005-02-03	Allergan, Inc.	Compositions containing alpha-2-adrenergic agonist components
EP1301210A2 (fr)	2000-07-14	2003-04-16	Allergan, Inc.	Compositions contenant des composants a activite therapeutique presentant une solubilite amelioree
NZ521185A (en) *	2000-07-14	2005-02-25	Allergan Inc	Compositions containing alpha-2-adrenergic agonist components
WO2002089853A2 (fr) *	2001-05-03	2002-11-14	Allergan, Inc.	Compositions ayant des caracteristiques pharmacocinetiques ameliorees
US20020198210A1 (en) *	2001-05-03	2002-12-26	Allergan Sales Inc.	Alpha-2-adrenergic agonist/fatty acid compositions
US20020198209A1 (en) *	2001-05-03	2002-12-26	Allergan Sales Inc.	Compositions having enhanced pharmacokinetic characteristics
US7030149B2 (en)	2002-04-19	2006-04-18	Allergan, Inc.	Combination of brimonidine timolol for topical ophthalmic use
US20040191332A1 (en) *	2003-03-27	2004-09-30	Allergan, Inc.	Preserved ophthalmic compositions
US8410102B2 (en)	2003-05-27	2013-04-02	Galderma Laboratories Inc.	Methods and compositions for treating or preventing erythema
US7439241B2 (en)	2003-05-27	2008-10-21	Galderma Laboratories, Inc.	Compounds, formulations, and methods for treating or preventing rosacea
ATE444732T1 (de)	2003-08-07	2009-10-15	Allergan Inc	Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
WO2008144399A1 (fr) *	2007-05-18	2008-11-27	Bausch & Lomb Incorporated	Complexes comprenant des agonistes du récepteur α2-adrénergique et compositions associées
US9192571B2 (en) *	2008-03-03	2015-11-24	Allergan, Inc.	Ketorolac tromethamine compositions for treating or preventing ocular pain
US7842714B2 (en) *	2008-03-03	2010-11-30	Allergan, Inc.	Ketorolac tromethamine compositions for treating ocular pain
US8952011B2 (en)	2008-08-01	2015-02-10	Eye Therapies Llc	Compositions and methods for the treatment of nasal conditions
US20110003823A1 (en) *	2008-08-01	2011-01-06	Alpha Synergy Development, Inc.	Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
US20100203165A1 (en) *	2008-08-01	2010-08-12	Gerald Horn	Compositions and methods for treatment of disorders or conditions of the eye
US20180369240A1 (en) *	2008-08-01	2018-12-27	Eye Therapies Llc	Preferential Vasoconstriction Compositions and Methods of Use
US20100202979A1 (en) *	2008-08-01	2010-08-12	Gerald Horn	Compositions and methods for treatment of pulmonary diseases and conditions
US20100197694A1 (en) *	2008-08-01	2010-08-05	Gerald Horn	Compositions and methods for treatment of diseases and conditions with increased vascular permeability
DK2320911T3 (da) *	2008-08-01	2014-11-03	Eye Therapies Llc	Vasokonstriktionspræparater og fremgangsmåder til anvendelse deraf
US8987270B2 (en)	2009-07-27	2015-03-24	Eye Therapies Llc	Formulations of selective alpha-2 agonists and methods of use thereof
EP2329849B1 (fr)	2009-11-18	2015-04-29	Galderma Research & Development	Combinaison d'un agoniste du récepteur alpha-2 adrénergique et d'un agent anti-inflammatoire non stéroïdien pour traiter ou empêcher un trouble cutané inflammatoire
US8394800B2 (en) *	2009-11-19	2013-03-12	Galderma Laboratories, L.P.	Method for treating psoriasis
US9522153B2 (en)	2009-12-22	2016-12-20	Allergan, Inc.	Compositions and methods for lowering intraocular pressure
WO2011117377A2 (fr)	2010-03-26	2011-09-29	Galderma Research & Development	Méthodes et compositions améliorées pour le traitement sûr et efficace de l'érythème
US8916562B2 (en)	2010-03-26	2014-12-23	Galderma Research & Development Snc	Methods and compositions for safe and effective treatment of telangiectasia
WO2011127139A2 (fr)	2010-04-07	2011-10-13	Allergan, Inc.	Combinaisons de compositions de conservation pour les formulations ophtalmiques
JP2013523828A (ja)	2010-04-07	2013-06-17	アラーガンインコーポレイテッド	眼科用組成物のための保存剤の組み合わせ
TR201818754T4 (tr)	2010-07-29	2019-01-21	Allergan Inc	Koruyucu içermeyen Brimonidin Ve Timolol Çözeltileri
NO2444068T3 (fr)	2010-10-21	2014-12-20
US8053427B1 (en)	2010-10-21	2011-11-08	Galderma R&D SNC	Brimonidine gel composition
JP6339364B2 (ja) *	2013-12-27	2018-06-06	カズマパートナーズ株式会社	無定形ブリモニジン酒石酸塩及びその製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE795970A (fr) *	1972-02-29	1973-08-27	Pfizer	Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
GB1463520A (en) *	1974-09-06	1977-02-02	Pfizer Ltd	Process for the production of imidazolines
US5077292A (en) *	1989-10-12	1991-12-31	Allergan, Inc.	(2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same

1989
- 1989-10-31 US US07/429,835 patent/US5021416A/en not_active Expired - Lifetime
1990
- 1990-09-12 CA CA002025189A patent/CA2025189A1/fr not_active Abandoned
- 1990-09-19 PH PH41224A patent/PH26978A/en unknown
- 1990-10-05 TW TW079108344A patent/TW218352B/zh active
- 1990-10-10 AU AU63966/90A patent/AU627626B2/en not_active Ceased
- 1990-10-15 ZA ZA908731A patent/ZA908731B/xx unknown
- 1990-10-22 IL IL96083A patent/IL96083A/xx not_active IP Right Cessation
- 1990-10-26 ES ES90311755T patent/ES2074138T3/es not_active Expired - Lifetime
- 1990-10-26 AT AT90311755T patent/ATE122233T1/de not_active IP Right Cessation
- 1990-10-26 DE DE69019297T patent/DE69019297T2/de not_active Expired - Fee Related
- 1990-10-26 EP EP90311755A patent/EP0426390B1/fr not_active Expired - Lifetime
- 1990-10-30 FI FI905369A patent/FI905369A0/fi not_active Application Discontinuation
- 1990-10-30 IE IE389690A patent/IE68413B1/en not_active IP Right Cessation
- 1990-10-30 HU HU906934A patent/HU207946B/hu not_active IP Right Cessation
- 1990-10-30 NZ NZ235884A patent/NZ235884A/xx unknown
- 1990-10-31 RU SU904831722A patent/RU1829937C/ru active
- 1990-10-31 JP JP2297019A patent/JP2999240B2/ja not_active Expired - Lifetime
- 1990-10-31 KR KR1019900017735A patent/KR910007530A/ko not_active Application Discontinuation

Also Published As

Publication number	Publication date
DE69019297D1 (de)	1995-06-14
RU1829937C (ru)	1993-07-23
FI905369A0 (fi)	1990-10-30
US5021416A (en)	1991-06-04
ES2074138T3 (es)	1995-09-01
IL96083A (en)	1997-06-10
JP2999240B2 (ja)	2000-01-17
IE68413B1 (en)	1996-06-12
HUT57045A (en)	1991-11-28
IL96083A0 (en)	1991-07-18
KR910007530A (ko)	1991-05-30
NZ235884A (en)	1997-08-22
ATE122233T1 (de)	1995-05-15
AU627626B2 (en)	1992-08-27
DE69019297T2 (de)	1995-10-12
JPH03153626A (ja)	1991-07-01
IE903896A1 (en)	1991-05-08
HU207946B (en)	1993-07-28
EP0426390B1 (fr)	1995-05-10
HU906934D0 (en)	1991-05-28
TW218352B (fr)	1994-01-01
EP0426390A3 (en)	1992-03-04
EP0426390A2 (fr)	1991-05-08
ZA908731B (en)	1991-07-31
AU6396690A (en)	1991-05-09
CA2025189A1 (fr)	1991-05-01

Publication	Publication Date	Title
US5021416A (en)	1991-06-04	Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5300504A (en)	1994-04-05	(2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
CA2173974C (fr)	2006-05-02	Modes d'utilisation de derives de la quinoxaline (2 - imidazolin - 2 - ylamino)
US5091528A (en)	1992-02-25	6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
US5112822A (en)	1992-05-12	(2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US6323204B1 (en)	2001-11-27	Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5198442A (en)	1993-03-30	(2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5326763A (en)	1994-07-05	Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5204347A (en)	1993-04-20	Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines
EP0420606A2 (fr)	1991-04-03	Utilisation de 2-cycloalkylamino oxazolines pour réduire ou maintenir la pression intraoculaire
IL97220A (en)	1995-12-08	(2-imidazolin-2-ylamino) tetrahydro-quinoxalines and pharmaceutical compositions comprising them
NZ237076A (en)	1997-07-27	(2-imidazolin-2-ylamino)-tetrahydroquinoxaline derivatives
PT97005B (pt)	1998-07-31	Processo de prparacao de (2-imidazolin-2-ilamino)tetra-hidroquinoxalinas e de composicoes farmaceuticas que as contem